Affiliation
Sligo General Hospital, The Mall, Co., Republic of Ireland.Issue Date
2009-10MeSH
AsthmaCholinergic Antagonists
Chronic Disease
Cost-Benefit Analysis
Humans
Ipratropium
Pulmonary Disease, Chronic Obstructive
Randomized Controlled Trials as Topic
Scopolamine Derivatives
Metadata
Show full item recordCitation
Anticholinergic treatment in airways diseases. 2009, 26 (10):908-19 Adv TherJournal
Advances in therapyDOI
10.1007/s12325-009-0074-xPubMed ID
19967500Additional Links
http://www.ncbi.nlm.nih.gov/pubmed?term=19967500Abstract
The prevalence of chronic airways diseases such as chronic obstructive pulmonary disease and asthma is increasing. They lead to symptoms such as a cough and shortness of breath, partially through bronchoconstriction. Inhaled anticholinergics are one of a number of treatments designed to treat bronchoconstriction in airways disease. Both short-acting and long-acting agents are now available and this review highlights their efficacy and adverse event profile in chronic airways diseases.Item Type
ArticleLanguage
enISSN
1865-8652ae974a485f413a2113503eed53cd6c53
10.1007/s12325-009-0074-x